Acrivon Therapeutics Ownership | Who Owns Acrivon Therapeutics?

Acrivon Therapeutics Ownership Summary

Acrivon Therapeutics is owned by 8.36% institutional investors, 14.94% insiders, and 76.70% retail investors. Ra capital management is the largest institutional shareholder, holding 21.66% of ACRV shares. HBM Healthcare Investments AG Ord is the top mutual fund, with 1.68% of its assets in Acrivon Therapeutics shares.

ACRV Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Acrivon Therapeutics	8.36%	14.94%	76.70%
Sector	Healthcare Stocks	35.56%	12.08%	52.36%
Industry	Biotech Stocks	35.43%	12.01%	52.56%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Ra capital management	8.34M	21.66%	$11.59M
Sands capital ventures	2.12M	5.51%	$2.95M
Wellington management group llp	888.13K	2.31%	$1.23M
Acadian asset management	845.97K	2.20%	$1.18M
Renaissance	758.44K	1.97%	$1.05M
Vanguard group	698.86K	1.81%	$1.68M
Marshall wace, llp	560.44K	1.46%	$779.01K
Two sigma investments, lp	389.39K	1.01%	$541.26K
Jane street group	239.69K	0.62%	$333.17K
Geode capital management	236.39K	0.61%	$328.69K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Sands capital ventures	2.12M	0.70%	$2.95M
Ra capital management	8.34M	0.12%	$11.59M
Gsa capital partners llp	186.72K	0.02%	$260.00K
Aaf wealth management	10.68K	0.01%	$14.84K
Bridgeway capital management	158.90K	0.00%	$220.87K
Prelude capital management	24.02K	0.00%	$33.38K
Two sigma securities	11.68K	0.00%	$16.23K
Acadian asset management	845.97K	0.00%	$1.18M
Renaissance	758.44K	0.00%	$1.05M
Xtx topco	66.88K	0.00%	$92.97K

Top Buyers

Holder	Shares	% Assets	Change
Acadian asset management	845.97K	0.00%	264.76K
Gsa capital partners llp	186.72K	0.02%	186.72K
Renaissance	758.44K	0.00%	124.27K
Bridgeway capital management	158.90K	0.00%	116.00K
Vanguard fiduciary trust	107.53K	-	107.53K

Top Sellers

Holder	Shares	% Assets	Change
Perceptive advisors	-	-	-5.36M
Citadel advisors	-	-	-1.64M
Acorn capital advisors	-	-	-405.24K
Ubs group	34.63K	-	-313.91K
Two sigma investments, lp	389.39K	0.00%	-195.67K

New Positions

Holder	Shares	% Assets	Change	Value
Gsa capital partners llp	186.72K	0.02%	186.72K	$260.00K
Vanguard fiduciary trust	107.53K	-	107.53K	$149.47K
Algert global	44.65K	0.00%	44.65K	$81.00K
Two sigma securities	11.68K	0.00%	11.68K	$16.23K
Vanguard global advisers	4.45K	-	4.45K	$6.19K

Sold Out

Holder	Change
True wealth design	-176.00
Sterling capital management	-198.00
Optima capital	-278.00
Gamma investing	-287.00
Eversource wealth advisors	-373.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	16	-66.67%	3,219,907	-82.70%	8	0.36%	8	-66.67%	1	-90.00%
Dec 31, 2025	7	-84.78%	1,075,876	-93.85%	2	0.14%	3	-81.25%	1	-94.44%
Sep 30, 2025	10	-80.77%	655,031	-96.32%	1	0.08%	5	-80.77%	3	-81.25%
Jun 30, 2025	51	-15.00%	17,796,335	-20.97%	46	1.34%	25	4.17%	16	-23.81%
Mar 31, 2025	4	-93.10%	14,129,412	-38.60%	36	1.01%	-	-100.00%	1	-92.86%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
HBM Healthcare Investments AG Ord	527.15K	1.68%	-39.51K
Vanguard Morn Total Stk Mkt Idx Investor	545.54K	1.27%	-
Vanguard Total Stock Mkt Idx Inv	545.54K	1.27%	-
Vanguard US Total Market Shares ETF	387.41K	1.24%	-
Vanguard Institutional Extnd Mkt Idx Tr	389.57K	0.91%	168.92K
Lago Erie SICAV	260.71K	0.61%	-
Fidelity Small Cap Index	129.48K	0.41%	-
iShares Biotechnology ETF	125.85K	0.40%	-
Fidelity Extended Market Index	156.88K	0.37%	45.55K
A4Investments SICAV SIF ACCI IlanaA2EURH	150.00K	0.35%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Aug 04, 2026	Levy Adam D.	Chief Financial Officer	Sell	$1.79K
Jul 21, 2026	Miller Mary	Chief Legal Officer	Sell	$1.01K
Jan 14, 2026	Blume-Jensen Peter	President and CEO	Buy	$82.12K
Jan 14, 2026	Levy Adam D.	Chief Financial Officer	Buy	$15.00K
Jan 13, 2026	Devroe Eric	Chief Operating Officer	Buy	$17.22K

Insider Transactions Trends

Date	Buy	Sell
2026 Q3	-	2
2026 Q2	-	-
2026 Q1	3	-
2025 Q4	-	-
2025 Q3	-	-

ACRV Ownership FAQ

Who Owns Acrivon Therapeutics?

Acrivon Therapeutics shareholders are primarily institutional investors at 8.36%, followed by 14.94% insiders and 76.70% retail investors. The average institutional ownership in Acrivon Therapeutics's industry, Biotech Stocks , is 35.43%, which Acrivon Therapeutics falls below.

Who owns the most shares of Acrivon Therapeutics?

Acrivon Therapeutics’s largest shareholders are Ra capital management (8.34M shares, 21.66%), Sands capital ventures (2.12M shares, 5.51%), and Wellington management group llp (888.13K shares, 2.31%). Together, they hold 29.48% of Acrivon Therapeutics’s total shares outstanding.

Does Blackrock own Acrivon Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Acrivon Therapeutics.

Who is Acrivon Therapeutics’s biggest shareholder by percentage of total assets invested?

Sands capital ventures is Acrivon Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.70% of its assets in 2.12M Acrivon Therapeutics shares, valued at 2.95M$.

Who is the top mutual fund holder of Acrivon Therapeutics shares?

HBM Healthcare Investments AG Ord is the top mutual fund holder of Acrivon Therapeutics shares, with 1.68% of its total shares outstanding invested in 527.15K Acrivon Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools